-+ 0.00%
-+ 0.00%
-+ 0.00%
Hualan Biotech announced that the application for clinical trial registration of the domestically produced drug of dupliumab injection developed by the participating company Hualan Ankang Biology Co., Ltd. was recently accepted by the State Drug Administration. The drug registration classification is Class 3.3 therapeutic biological product, with a specification of 300 mg/stick. The indications include atopic dermatitis, asthma, pruritus nodules, chronic obstructive pulmonary disease, and bullous pemphigoid. The drug is a biosimilar, and the application has been submitted to the Drug Evaluation Center of the State Drug Administration for review and approval; the timing and results of the clinical registration approval are uncertain, and there will be no impact on the company's recent performance.
Share
Listen to the news
Hualan Biotech announced that the application for clinical trial registration of the domestically produced drug of dupliumab injection developed by the participating company Hualan Ankang Biology Co., Ltd. was recently accepted by the State Drug Administration. The drug registration classification is Class 3.3 therapeutic biological product, with a specification of 300 mg/stick. The indications include atopic dermatitis, asthma, pruritus nodules, chronic obstructive pulmonary disease, and bullous pemphigoid. The drug is a biosimilar, and the application has been submitted to the Drug Evaluation Center of the State Drug Administration for review and approval; the timing and results of the clinical registration approval are uncertain, and there will be no impact on the company's recent performance.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending